Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosylate sedation in ECMO patients
ChiCTR2400094871Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in respiratory failure, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Proportion of time within target RASS range during ECMO without rescue medication. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
respiratory failure
Beyond the preview
Go deeper on ChiCTR2400094871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094871.